Author

Caitlyn Weston

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Adrian Gerold SacheriD· 1 shared Alexander Wang YingiD· 1 shared Cigall KadochiD· 1 shared Claudia Gentile· 1 shared Daren C. CardiD· 1 shared Florence T.H. WuiD· 1 shared Francesco FacchinettiiD· 1 shared Jens KöhleriD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrian Gerold SacherORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion

Claudia Gentile, William W. Feng, Sean M. Lenahan, Alexander Wang Ying, Daren C. Card, Florence T.H. Wu, Nhu‐An Pham, Nikolina Radulovich, Pinjiang Mary Cao, K. Hueniken, Quan Li, Ming‐Sound Tsao, JOSEPH S. KULESZA, Madeline M. Hinkley, Lishu Liao, , Cigall Kadoch

This study shows that inhibiting mSWI/SNF complexes enhances the effectiveness of KRAS inhibitors in lung cancers by reversing epithelial-mesenchymal transition resistance.

bioRxiv · Mar 1, 2026 · PreprintCancer Biology